BonGeo Pharmaceuticals Inc. Sustainability Profile
BonGeo Pharmaceuticals Inc., headquartered in the United States, is a prominent player in the biopharmaceutical industry, specialising in innovative therapies for chronic diseases. Founded in 2010, the company has made significant strides in research and development, focusing on areas such as oncology and autoimmune disorders. With a commitment to advancing healthcare, BonGeo Pharmaceuticals offers a unique portfolio of biologics and small molecule drugs that stand out for their efficacy and safety profiles. The company has achieved notable milestones, including successful clinical trials and strategic partnerships that enhance its market position. Recognised for its dedication to quality and innovation, BonGeo Pharmaceuticals continues to expand its operational reach, aiming to improve patient outcomes globally while maintaining a strong presence in the US and other key markets.
DitchCarbon Score
How does BonGeo Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BonGeo Pharmaceuticals Inc.'s score of 3 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
BonGeo Pharmaceuticals Inc.'s reported carbon emissions
BonGeo Pharmaceuticals Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that BonGeo Pharmaceuticals may not have established formal commitments to address carbon emissions or climate change initiatives at this time. As the pharmaceutical industry increasingly prioritises sustainability, it will be essential for BonGeo Pharmaceuticals to consider developing and communicating its climate commitments to align with industry standards and expectations.
How Carbon Intensive is BonGeo Pharmaceuticals Inc.'s Industry?
How Carbon Intensive is BonGeo Pharmaceuticals Inc.'s Location?
BonGeo Pharmaceuticals Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
BonGeo Pharmaceuticals Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
